-
Mashup Score: 1
In an interview with Targeted Oncology, Ruben Mesa, director, MD, discussed the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Srdan Verstovsek, MD, PhD, shares his take home message from his presentation on accelerated and blastic phase myeloproliferative neoplasms during the first Annual Texas MPM Workshop.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
During the 1st Annual Texas MPM Workshop, Aaron Gerds, MD, MS presented on the ruxolitinib in the present and future, as well as the possibilities for moving beyond the JAK-STAT pathway.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Patients considered to have early myelofibrosis are a heterogeneous group for whom disease risk, best treatment strategies, and the probability of mortality are best determined individually by looking at patient’s clinical characteristics and molecular markers together.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Patients considered to have early myelofibrosis are a heterogeneous group for whom disease risk, best treatment strategies, and the probability of mortality are best determined individually by looking at patient’s clinical characteristics and molecular markers together.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
During the 1st Annual Texas MPM Workshop, Aaron Gerds, MD, MS presented on the ruxolitinib in the present and future, as well as the possibilities for moving beyond the JAK-STAT pathway.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
International interactive virtual workshop on the biology and therapy of Myeloproliferative Neoplasms co-led by Dr. Ruben Mesa (Mays Cancer Center at UT
Source: SymplurCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Texas Virtual MPN Workshop | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways - 4 year(s) ago
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
In an interview with Targeted Oncology, Ruben Mesa, director, MD, discussed the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Texas MPN Workshop 2020 | VJHemOnc - 4 year(s) ago
Skip to contentAboutEditorial BoardExpert indexCookie PolicyTerms of UsePrivacy PolicyEditorial policySign upContactNewsletters Visit Home (current) Diseases CLL Multiple Myeloma Lymphoma MDS Amyloidosis MPNs AML CML ALL View all Diseases Topics Transplantation Measurable Residual Disease Real-World Data CAR-T & Cellular Therapy Immuno-Oncology Diagnosis…
Source: VJHemOncCategories: Hem/Oncs, Latest HeadlinesTweet
"My key takeaway is to be incredibly hopeful for having such a robust set of therapies...many of which are active, credible, and we might have, 2 years from now, multiple approved agents that might have a variety of different pathways..." https://t.co/wKLfSDUDxI #mpnsm #TxMPN2020